GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi

Global Blood Therapeutics Inc GBT has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA SNY.

  • One program pursues a novel anti-sickling mechanism, and the other leverages a new approach to reduce inflammation and oxidative stress.
  • Sanofi's Bioverativ subsidiary's programs supplement GBT's existing pipeline and support the company's strategy to address sickle cell disease from multiple approaches.
  • Under the terms of the agreement, GBT will conduct all research, development, regulatory, and commercialization activities worldwide.
  • Sanofi will receive an upfront payment and is entitled to payments up to approximately $353 million in milestone payments and single-digit tiered royalties on worldwide net sales.
  • Price Action: GBT shares are up 0.2% at $46.1, and SNY shares are up 0.4% at $48.9 in premarket on the last check Tuesday.
Loading...
Loading...
SNY Logo
SNYSanofi SA
$53.100.64%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
58.82
Growth
31.82
Quality
29.25
Value
50.22
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...